EU Partners

University of Patras, Department of Pharmacy, Patras, Greece (UPAT)

The University of Patras (UPAT) is the third largest University in Greece in terms of students, faculty members, administrative personnel, number of departments and degrees awarded. Besides its distinguished path in education, the UPAT excels in various fields of basic and applied research. Its departments, laboratories and clinics have been recognized as centres of excellence on the basis of international assessment. UPAT had 27 projects funded by EC. The Laboratory of Pharmacogenomics and Individualized Therapy of the Department of Pharmacy, UPAT, is the first laboratory of pharmacogenomics and individualized therapy in Greek Academia and is actively involved in research, clinical studies, training and provision of services in the field of Pharmacogenomics and Individualized Therapy. It is world-renowned for its expertise and high level of wet-lab, and dry-lab as well as public health research, all mainly focused on the field of pharmacogenomics and individualized therapy and has successfully participated in many international consortia and research programs, having a significant publication track-record in high-quality scientific journals.

Head of the Laboratory of Pharmacogenomics and Individualized Therapy, Prof. George P. Patrinos, PhD in Molecular Biology and Genetics, currently serves as Associate Professor of Pharmacogenomics and Pharmaceutical Biotechnology in the UPAT, Department of Pharmacy and holds adjunct Professorships at Erasmus MC, Faculty of Medicine, Rotterdam (the Netherlands) and the United Arab Emirates University, College of Medicine, Department of Pathology, Al-Ain (UAE). Also, he is Greece’s National representative in the CHMP Pharmacogenomics Working Party of the European Medicines Agency (EMA, London, UK) and Scientific Director of the Golden Helix Foundation (London, UK), an international non-profit research organization in the field of Genomic Medicine.

His research interests involve discovery work and clinical implementation of pharmacogenomics, genomics of rare disorders and transcriptional regulation of human fetal globin genes. His group is also internationally recognized for its involvement in developing National/Ethnic Genetic databases to document the genetic heterogeneity in different populations worldwide and of genome informatics tools to translate genomic information into a clinically meaningful format, while he also has a keen interest in public health genomics to critically assess the impact of genomics to society and public health.

George Patrinos has more than 200 publications in peer-reviewed scientific journals and textbooks, some of them in leading scientific journals, such as Nature Genetics, Nature Reviews Genetics, Nucleic Acids Research, Genes and Development. His publications are cited more than 9700 times, h-index 45.

University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia (UL)

The University of Ljubljana (UL) is the central and largest educational institution in Slovenia. It is also the central and largest research institution in Slovenia with 30 percent of all registered researchers. Up to now, UL has been involved in 201 HORIZON2020 projects (including 4 ERC grants, 2 ERA-CHAIR, 1 Twinning project and 33 Marie Skłodowska-Curie Actions), 208 ERASMUS projects and 112 projects of the European territorial cooperation programme.

The research in Pharmacogenetic Laboratory at Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, UL is focused on understanding the basis of differences between individuals in human drug metabolism with the emphasis on genetic polymorphisms of the genes encoding drug transporters, drug metabolizing enzymes, drug targets and enzymes involved in defense against oxidative stress and DNA repair. Pharmacogenetic Laboratory has been involved into Horizon 2020 project Ubiquitous Pharmacogenomics (U-PGx).

Head and founder of Pharmacogenetic Laboratory, Prof. Vita Dolzan, MD and PhD in Biochemistry and Molecular biology is a Full Professor of Biochemistry and Molecular Biology at the Faculty of Medicine, UL, where she lectures Biochemistry, Molecular Biology and Pharmacogenetics at the undergraduate and graduate level. Her research interests are focused on applied research in the field of pharmacogenetics and on implementation of novel molecular biology-based methods into clinical use. She is a member of the European Research Network on Pharmacogenetics/genomics and a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC). She published over 70 research papers that have been cited over 2000 times.

University of Trieste, Department of Medicine, Surgery and Health Sciences,
Trieste, Italy (UT)

The University of Trieste (UNITS) is a research-intensive university, ranked among the best universities in the world and in Italy.  Recently it has been placed at highest level of judgement (“A-label”) by the Italian Agency for Quality Assurance of the Ministry of Education. The University of Trieste has 95 projects funded by EC. The Department of Medicine, Surgical and Health Sciences at the University of Trieste conducts both scientific research and educational as well as healthcare activities.

Department of Life Sciences Research group Molecular pharmaceutics and pharmacogenomics focuses on the identification and study of the molecular and cellular characteristics that can be used to personalize treatment. Several research lines address pharmacogenomics and personalization of therapy for various diseases as well as in vitro mechanistic studies on the pharmacokinetics, pharmacodynamics and pharmacogenomics of immunosuppressive and anti-leukemic drugs, including iPSC technology used to create new possibilities for modeling diseases and controlling adverse effects of drugs in a more personalized way.

Prof. Giuliana Decorti, MD, PhD in Clinical Pharmacology is an associated professor of Pharmacology at the Faculty of Medicine of the University of Trieste. Giuliana Decorti’s present most studies concern the pharmacogenetics of enzymes involved in the pharmacodynamic/pharmacokinetics of drugs employed in inflammatory bowel disease and acute lymphoblastic leukemia, particularly in children. She has more than 200 publications, cited more than 3000 times, h-index 32.